Evidence map›Paper›PMID 33068776›Full record

ReviewMolecular metabolism2021

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier

4 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 762 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
762citing papers in PubMed, 16 pooled it
74.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06243536 phase4unknown statusstarted 2024, after this paper: background citation

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

Ran2024Enrolled60Registered outcomes3Posted comparisons0ConditionsDisordered Eating Behaviors, Overweight, Type 2 DiabetesArmssemaglutide, Standard of care
PMID 27208320PMID 25870084PMID 36722623PMID 25330463PMID 25745131PMID 24245943PMID 21157325PMID 19336687PMID 17498508PMID 16682865PMID 11728508PMID 26301188other papers from this trial
Open the trial in the graph
NCT06475586 phase4completedstarted 2023, after this paper: background citation

Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Ran2023Enrolled30Registered outcomes10Posted comparisons0ConditionsDiabetes Type 2, Psoriasis VulgarisArmssemaglutide
PMID 34463640other papers from this trial
Open the trial in the graph
NCT05227820 phase2completednot on this mapstarted 2022, after this paper: background citation

Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias

TypeinterventionalSponsorNeurological Associates of West Los AngelesRan2022 to 2022Enrolled23ConditionsAlzheimer DiseaseArmsNE3107
NCT06055829 completednot on this mapstarted 2022, after this paper: background citation

The Adjustment of Doses in Diabetes Mellitus Can Lead to Fluctuation of Glucose Level in Type I

Typeobservational_patient_registrySponsorLiwa CollegeRan2022 to 2023Enrolled1ConditionsDiabetes Mellitus, Type 1ArmsInsulin injection and blood glucose
3 · Its place in the literature

Who cites it

762 citing papers in PubMed, 16 syntheses or guidelines pooled it, 1,406 citations in OpenAlex.

  1. Comparing GLP-1 agonists versus other weight loss interventions on risk of atrial fibrillation recurrence after catheter ablation: a meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

702 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael A NauckDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. Electronic address: michael.nauck@rub.de.
Daniel R QuastDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Jakob WefersDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Juris J MeierDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
St. Josef-Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals between injections (twice daily for exenatide b.i.d.). SCOPE OF REVIEW: To summarize current knowledge about GLP-1 receptor agonist. MAJOR

conclusionsAt present, GLP-1 RAs are injected twice daily (exenatide b.i.d.), once daily (lixisenatide and liraglutide), or once weekly (exenatide once weekly, dulaglutide, albiglutide, and semaglutide). A daily oral preparation of semaglutide, which has demonstrated clinical effectiveness close to the once-weekly subcutaneous preparation, was recently approved. All GLP-1 RAs share common mechanisms of action: augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying preventing large post-meal glycemic increments, and a reduction in calorie intake and body weight. Short-acting agents (exenatide b.i.d., lixisenatide) have reduced effectiveness on overnight and fasting plasma glucose, but maintain their effect on gastric emptying during long-term treatment. Long-acting GLP-1 RAs (liraglutide, once-weekly exenatide, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAnimalsBlood GlucoseBody WeightCardiovascular SystemDiabetes Mellitus, Type 2ExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesHumansHypoglycemiaImmunoglobulin Fc FragmentsInsulinLiraglutideBlood GlucosedulaglutideExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesImmunoglobulin Fc FragmentsInsulinLiraglutidelixisenatidePeptidesRecombinant Fusion ProteinsrGLP-1 proteinSemaglutideAlbiglutideBody weightCardiovascular diseaseDulaglutideExenatideGlucagon-like peptide-1 receptor agonistsLiraglutideLixisenatideSemaglutideType 2 diabetes

Identifiers

PMID33068776
PMCPMC8085572
OpenAlexW3093042356

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.